Consumption of drugs for Alzheimer’s disease on the Brazilian private market

Detalhes bibliográficos
Autor(a) principal: Freitas, Evani Leite de
Data de Publicação: 2023
Outros Autores: Calil-Elias, Sabrina, Erbisti, Rafael Santos, Grinberg-Weller, Branca, Miranda, Elaine Silva
Tipo de documento: Artigo
Idioma: por
eng
Título da fonte: Revista de Saúde Pública
Texto Completo: https://www.revistas.usp.br/rsp/article/view/220145
Resumo: OBJECTIVE: To analyze the consumption of drugs for Alzheimer’s disease on the Brazilian private market and its geographical distribution from 2014 to 2020. METHODS: National data from the Brazilian National System of Controlled Product Management were used, regarding sales of donepezil, galantamine, rivastigmine, and memantine from January 2014 to December 2020. Sales data were used as a proxy for drug consumption and expressed as defined daily dose/1,000 inhabitants/year at national, regional, federative unit and microregion levels. RESULTS: Drug consumption went from 5,000 defined daily doses/1,000 inhabitants, in 2014, to more than 16,000/1,000 inhabitants, in 2020, and all federative units showed positive variation. The Brazilian Northeast had the highest cumulative consumption in the period but displayed microregional disparities while the North region had the lowest consumption. Donepezil and memantine were the most consumed drugs, with the highest growth in consumption from 2014 to 2020. CONCLUSION: The consumption of medicines indicated to treat Alzheimer’s disease tripled in Brazil between 2014 and 2020, which may relate to the increase in the prevalence of the disease in the country, greater access to health services, and inappropriate use. This challenges managers and healthcare providers due to population aging and the increased prevalence of chronic-degenerative diseases.
id USP-23_2dd6197d70e73cb4309248f933e7af7d
oai_identifier_str oai:revistas.usp.br:article/220145
network_acronym_str USP-23
network_name_str Revista de Saúde Pública
repository_id_str
spelling Consumption of drugs for Alzheimer’s disease on the Brazilian private marketConsumo de medicamentos para doença de Alzheimer no mercado privado brasileiroAlzheimer’s DiseaseDrug Utilization DementiaPrescription DrugsDrugs from the Specialized Component of Pharmaceutical CareDoença de Alzheimer Uso de MedicamentosDemênciaMedicamentos sob PrescriçãoMedicamentos do Componente Especializado da Assistência FarmacêuticaOBJECTIVE: To analyze the consumption of drugs for Alzheimer’s disease on the Brazilian private market and its geographical distribution from 2014 to 2020. METHODS: National data from the Brazilian National System of Controlled Product Management were used, regarding sales of donepezil, galantamine, rivastigmine, and memantine from January 2014 to December 2020. Sales data were used as a proxy for drug consumption and expressed as defined daily dose/1,000 inhabitants/year at national, regional, federative unit and microregion levels. RESULTS: Drug consumption went from 5,000 defined daily doses/1,000 inhabitants, in 2014, to more than 16,000/1,000 inhabitants, in 2020, and all federative units showed positive variation. The Brazilian Northeast had the highest cumulative consumption in the period but displayed microregional disparities while the North region had the lowest consumption. Donepezil and memantine were the most consumed drugs, with the highest growth in consumption from 2014 to 2020. CONCLUSION: The consumption of medicines indicated to treat Alzheimer’s disease tripled in Brazil between 2014 and 2020, which may relate to the increase in the prevalence of the disease in the country, greater access to health services, and inappropriate use. This challenges managers and healthcare providers due to population aging and the increased prevalence of chronic-degenerative diseases.OBJETIVO: Analisar o consumo de medicamentos para a doença de Alzheimer no mercado privado brasileiro e sua distribuição geográfica entre os anos de 2014 e 2020. MÉTODOS: Foram utilizados dados do Sistema Nacional de Gerenciamento de Produtos Controlados relativos às vendas de donepezila, galantamina, rivastigmina e memantina, entre janeiro de 2014 a dezembro de 2020, em todo o território nacional. Os dados de venda foram utilizados como proxy para o consumo dos medicamentos, avaliado em dose diária definida (DDD)/1.000 habitantes/ano em nível nacional, regional, por unidade federativa e microrregião. RESULTADOS: O consumo dos medicamentos passou de 5.000 DDD/1.000 habitantes em 2014 para mais de 16.000 DDD/1.000 habitantes em 2020, e todas as unidades de federação apresentaram variação positiva. A região Nordeste apresentou o maior consumo acumulado no período, porém exibiu disparidades microrregionais. A região Norte apresentou o menor consumo. Os medicamentos mais consumidos foram donepezila e memantina, os quais também apresentaram maior crescimento do consumo no intervalo de tempo entre os anos de 2014 e 2020. CONCLUSÃO: O consumo de medicamentos para o tratamento da doença de Alzheimer triplicou no Brasil entre os anos de 2014 e 2020, o que pode estar relacionado ao aumento da prevalência da doença no país e/ou maior acesso a serviços de saúde, assim como estar ligado, também, à utilização inapropriada destes medicamentos. Este é um desafio para gestores e profissionais de saúde num cenário de envelhecimento populacional e aumento da prevalência de doenças crônico-degenerativas.Universidade de São Paulo. Faculdade de Saúde Pública2023-11-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdftext/xmlhttps://www.revistas.usp.br/rsp/article/view/22014510.11606/s1518-8787.2023057005128Revista de Saúde Pública; Vol. 57 No. 1 (2023); 83Revista de Saúde Pública; Vol. 57 Núm. 1 (2023); 83Revista de Saúde Pública; v. 57 n. 1 (2023); 831518-87870034-8910reponame:Revista de Saúde Públicainstname:Universidade de São Paulo (USP)instacron:USPporenghttps://www.revistas.usp.br/rsp/article/view/220145/200958https://www.revistas.usp.br/rsp/article/view/220145/200957https://www.revistas.usp.br/rsp/article/view/220145/200956Copyright (c) 2023 Evani Leite de Freitas, Sabrina Calil-Elias, Rafael Santos Erbisti, Branca Grinberg-Weller, Elaine Silva Mirandahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessFreitas, Evani Leite deCalil-Elias, SabrinaErbisti, Rafael SantosGrinberg-Weller, BrancaMiranda, Elaine Silva2023-12-12T13:54:58Zoai:revistas.usp.br:article/220145Revistahttps://www.revistas.usp.br/rsp/indexONGhttps://www.revistas.usp.br/rsp/oairevsp@org.usp.br||revsp1@usp.br1518-87870034-8910opendoar:2023-12-12T13:54:58Revista de Saúde Pública - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Consumption of drugs for Alzheimer’s disease on the Brazilian private market
Consumo de medicamentos para doença de Alzheimer no mercado privado brasileiro
title Consumption of drugs for Alzheimer’s disease on the Brazilian private market
spellingShingle Consumption of drugs for Alzheimer’s disease on the Brazilian private market
Freitas, Evani Leite de
Alzheimer’s Disease
Drug Utilization
Dementia
Prescription Drugs
Drugs from the Specialized Component of Pharmaceutical Care
Doença de Alzheimer
Uso de Medicamentos
Demência
Medicamentos sob Prescrição
Medicamentos do Componente Especializado da Assistência Farmacêutica
title_short Consumption of drugs for Alzheimer’s disease on the Brazilian private market
title_full Consumption of drugs for Alzheimer’s disease on the Brazilian private market
title_fullStr Consumption of drugs for Alzheimer’s disease on the Brazilian private market
title_full_unstemmed Consumption of drugs for Alzheimer’s disease on the Brazilian private market
title_sort Consumption of drugs for Alzheimer’s disease on the Brazilian private market
author Freitas, Evani Leite de
author_facet Freitas, Evani Leite de
Calil-Elias, Sabrina
Erbisti, Rafael Santos
Grinberg-Weller, Branca
Miranda, Elaine Silva
author_role author
author2 Calil-Elias, Sabrina
Erbisti, Rafael Santos
Grinberg-Weller, Branca
Miranda, Elaine Silva
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Freitas, Evani Leite de
Calil-Elias, Sabrina
Erbisti, Rafael Santos
Grinberg-Weller, Branca
Miranda, Elaine Silva
dc.subject.por.fl_str_mv Alzheimer’s Disease
Drug Utilization
Dementia
Prescription Drugs
Drugs from the Specialized Component of Pharmaceutical Care
Doença de Alzheimer
Uso de Medicamentos
Demência
Medicamentos sob Prescrição
Medicamentos do Componente Especializado da Assistência Farmacêutica
topic Alzheimer’s Disease
Drug Utilization
Dementia
Prescription Drugs
Drugs from the Specialized Component of Pharmaceutical Care
Doença de Alzheimer
Uso de Medicamentos
Demência
Medicamentos sob Prescrição
Medicamentos do Componente Especializado da Assistência Farmacêutica
description OBJECTIVE: To analyze the consumption of drugs for Alzheimer’s disease on the Brazilian private market and its geographical distribution from 2014 to 2020. METHODS: National data from the Brazilian National System of Controlled Product Management were used, regarding sales of donepezil, galantamine, rivastigmine, and memantine from January 2014 to December 2020. Sales data were used as a proxy for drug consumption and expressed as defined daily dose/1,000 inhabitants/year at national, regional, federative unit and microregion levels. RESULTS: Drug consumption went from 5,000 defined daily doses/1,000 inhabitants, in 2014, to more than 16,000/1,000 inhabitants, in 2020, and all federative units showed positive variation. The Brazilian Northeast had the highest cumulative consumption in the period but displayed microregional disparities while the North region had the lowest consumption. Donepezil and memantine were the most consumed drugs, with the highest growth in consumption from 2014 to 2020. CONCLUSION: The consumption of medicines indicated to treat Alzheimer’s disease tripled in Brazil between 2014 and 2020, which may relate to the increase in the prevalence of the disease in the country, greater access to health services, and inappropriate use. This challenges managers and healthcare providers due to population aging and the increased prevalence of chronic-degenerative diseases.
publishDate 2023
dc.date.none.fl_str_mv 2023-11-08
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/rsp/article/view/220145
10.11606/s1518-8787.2023057005128
url https://www.revistas.usp.br/rsp/article/view/220145
identifier_str_mv 10.11606/s1518-8787.2023057005128
dc.language.iso.fl_str_mv por
eng
language por
eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/rsp/article/view/220145/200958
https://www.revistas.usp.br/rsp/article/view/220145/200957
https://www.revistas.usp.br/rsp/article/view/220145/200956
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
text/xml
dc.publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Saúde Pública
publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Saúde Pública
dc.source.none.fl_str_mv Revista de Saúde Pública; Vol. 57 No. 1 (2023); 83
Revista de Saúde Pública; Vol. 57 Núm. 1 (2023); 83
Revista de Saúde Pública; v. 57 n. 1 (2023); 83
1518-8787
0034-8910
reponame:Revista de Saúde Pública
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Revista de Saúde Pública
collection Revista de Saúde Pública
repository.name.fl_str_mv Revista de Saúde Pública - Universidade de São Paulo (USP)
repository.mail.fl_str_mv revsp@org.usp.br||revsp1@usp.br
_version_ 1800221804060475392

Registros relacionados